This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 µm) with a rapid resorption polymer (3 months). Theoretically, it presents less risk of inflammation of the vessel due to the kinetics of drug elution and polymer degradation. The objective of this study was to test the safety and efficacy of the new device....
This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting...
This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with...
This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and systolic blood pressure between 125 and 139 mm Hg (pre hypertensive stage) together with 2 risk factors. All patients underwent coronary intravascular ultrasonography (IVUS) and randomized to aliskiren 300 mg (305 patients) or placebo (308 patients). At 72...
Induction apoA-1 synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1 synthesis with favorable effect on HDL cholesterol. The impact of this drug on cholesterol plaque has not been investigated in humans. The objective of this study was to test the effects of RVX-208 100 mg twice a...
1. ESTUDIOS DE TECNOLOGIAS EN INTERVENCIONES CORONARIAS • RIBS IV – Presentador: Fernando Alfonso • ABSORB II – Presentador: Patrick Serruys 2. ESTUDIOS DE FARMACOLOGIA EN INTERVENCIONES CORONARIAS • ISAR-TRIPLE – Presentador: Nikolaus Sarafoff • SECURITY – Presentador: Antonio Colombo • BRIGHT – Presentador: Yalin Hang 3. ESTUDIOS EN IMÁGENES CORONARIAS • IVUS-CTO – Presentador:...
Original title: The ABSORB EXTEND Study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Reference: Alexandre Abizaid et al. EuroIntervention 2015;10:1396-1401. The safety and efficacy of the Absorb Bioresorbable Vascular Scaffold (Absorb BVS) has been previously shown in 131 patients of the ABSORB trial cohorts A and B. Following this trial, the prospective...
Original title: Frecuency domain optical coherente tomography to assess non-ostial left main artery. Reference: Francesco Burzotta, et al. EuroIntervention 2015;10e1-e8 Optical coherence tomography (OCT) has proved valuable in making decisions and monitoring stents implanted in coronary arteries, but its role in the assessment of left main (LM) lesions remains unclear. The study included 54 patients presenting moderate...
Original title: Validation and Comparison of the Long-Term Prognostic Capability of SYNTAX Store-II Among 1528 Consecutive Patients Who Underwent Left Main Percutaneous Coronary Intervention. Reference: Bo Xu, et al. JACC Cardiovascular Intervention 2014;7:1128-37. The SYNTAX angiography score is useful when deciding revascularization in multivessel, but with the addition of clinical variables in the second version, SYNTAX score...
Original title: Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions. Results of the International Survey on Interventional Strategy. Reference: Gabor G. Toth et al. CircCardiovascInterv. 2014. Epubahead of print. Measurement of fractional flow reserve (FFR) is recommended by the guidelines and supported by evidence in intermediate lesions when not any proof of ischemia is available...